Compare MIRM & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | HLN |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United Kingdom |
| Employees | N/A | 24524 |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 41.1B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | HLN |
|---|---|---|
| Price | $93.48 | $9.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $119.85 | N/A |
| AVG Volume (30 Days) | 899.6K | ★ 9.0M |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $26.22 | $6.55 |
| Revenue Next Year | $22.04 | $4.42 |
| P/E Ratio | ★ N/A | $49.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.37 | $8.65 |
| 52 Week High | $114.99 | $11.28 |
| Indicator | MIRM | HLN |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 48.07 |
| Support Level | $87.26 | $9.04 |
| Resistance Level | $98.03 | $9.44 |
| Average True Range (ATR) | 4.55 | 0.12 |
| MACD | -1.14 | 0.00 |
| Stochastic Oscillator | 22.14 | 63.27 |
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.